Vijay Pande's latest venture, VZVC, is a far cry from the massive biotech practice he left behind at a16z just last year. With a staggering $4 billion to deploy, Pande has taken a more measured approach, focusing on AI-native solutions rather than traditional discovery-based research. This shift in strategy reflects a growing recognition within the industry that biology is no longer solely about discovering new biological processes but also about engineering them for better treatments and therapies.
Despite his significant investment in VZVC, Pande remains resolute in his commitment to making clinical trials more feasible and affordable. He believes that the current system is "brutally expensive" and that only by pooling resources and sharing data can AI transform medicine. This is a far cry from the traditional model where researchers would spend millions on expensive trials before seeing any results.
The open, shared datasets Pande envisions are crucial in unlocking AI's potential to tackle complex medical problems. By releasing their work and collaborating with others, researchers can accelerate discovery, reduce costs, and ultimately improve patient outcomes. This approach is not only more feasible but also likely to yield more robust and reliable results, as the data can be combined and analyzed in new and innovative ways. As Pande's firm continues to grow and mature, it remains to be seen whether this shift towards an "engineering" science will become the norm or remain a rare exception within the industry.